Background. Different anticancer drugs are used in combination or alone to treat breast cancer depending upon the status of the patient. Oncologists need to know a drug’s efficacy; therefore, they compare different chemotherapies by considering side effects and overall survival so that suitable drugs can be prescribed. We present a comparison of adjuvant chemotherapies treating breast cancer with docetaxel plus cyclophosphamide (TC) and doxorubicin plus cyclophosphamide (AC) showing pathological markers and overall survival.
Method. For 4 to 8 cycles, (after every 21 days) out of 358 patients, 189 received TC (140 ml/m2 of docetaxel (IV) plus 1000 mg/m2 of cyclophosphamide) and 169 women were treated with AC (50/100 ml/m2 of doxorubicin (IV) plus 1000 mg/m2 of cyclophosphamide. On the basis of patients’ assessment by pathological markers, side effects of docetaxel, doxorubicin and cyclophosphamide are listed in our database using R programming language. The common factors and side effects given in MedlinePlus, NIH US database and from our database are separated to be included in comparison for this study. Statistically, we used Chi-Square Test for Homogeneity of Proportions at α = 0.05.
Results. There was no significant difference between proportions of patients with vomiting, extreme tiredness, diarrhoea, mild anaemia, stability and overall survival because p value > 0.05. However, p value < 0.05 for AC remains less toxic by 22.6%, 25.7% and 25.3% than TC in changes in taste, muscle pain and hands burning respectively, whereas TC remains less toxic by 52.9%, 26.3%, 11.3%, 32.5%, 15.5% and 1.75% in dizziness, sore throat, moderate anaemia, weight loss, blood transfusion and haemoglobin level respectively.
Discussion. TC is less toxic than AC in more aspects, whereas both combinations have same overall survival rate.
If you have any questions about submitting your review, please email us at email@example.com.